TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07184619: Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Sponsor: Newron Pharmaceuticals SPA · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$4,187,296

Rescue Site Savings

+$2,754,800

Unlock Full NCT07184619 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07184619 Rescue Dossier →